PUBLISHER: The Business Research Company | PRODUCT CODE: 1945387
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945387
Insulin pens, syringes, pumps, and injectors play a crucial role in regulating the blood glucose levels of diabetic individuals. These tools can be either reusable or disposable and are employed for the purpose of delivering the required insulin dosage into the bloodstream of diabetic patients.
The primary categories of insulin delivery devices and equipment encompass pens, injectors, pumps, and syringes. A syringe serves as an instrument for introducing or extracting fluids. Both reusable and disposable pens are utilized for insulin administration. Pumps are available in two forms, including tube pumps and tubeless pumps. These devices find applications in a variety of settings, such as hospitals, home care, and others.
Tariffs are impacting the insulin pens, syringes, pumps, and injectors market by increasing costs of imported plastics, electronic components, micro-needles, and precision molding equipment. North America and Europe are most affected due to reliance on global component sourcing, while Asia-Pacific faces pricing pressure on device exports. These tariffs are increasing device prices and affecting affordability for patients. However, they are also encouraging local manufacturing, regional assembly of insulin devices, and innovation in cost-effective delivery solutions.
The insulin pens, syringes, pumps and injectors market research report is one of a series of new reports from The Business Research Company that provides insulin pens, syringes, pumps and injectors market statistics, including insulin pens, syringes, pumps and injectors industry global market size, regional shares, competitors with a insulin pens, syringes, pumps and injectors market share, detailed insulin pens, syringes, pumps and injectors market segments, market trends and opportunities, and any further data you may need to thrive in the insulin pens, syringes, pumps and injectors industry. This insulin pens, syringes, pumps and injectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The insulin pens, syringes, pumps and injectors market size has grown rapidly in recent years. It will grow from $23.52 billion in 2025 to $26.14 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising prevalence of diabetes, increasing use of insulin therapy, expansion of homecare treatment models, availability of disposable insulin delivery devices, growth in patient self-management.
The insulin pens, syringes, pumps and injectors market size is expected to see rapid growth in the next few years. It will grow to $40.45 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to increasing adoption of connected diabetes devices, rising focus on automated insulin delivery, expansion of digital diabetes management platforms, growing investments in wearable insulin technologies, increasing demand for minimally invasive delivery systems. Major trends in the forecast period include increasing adoption of smart insulin delivery devices, rising use of patch and tubeless pumps, growing demand for home-based diabetes management, expansion of connected insulin monitoring systems, enhanced focus on patient convenience.
The growing prevalence of diabetes worldwide is driving the expansion of the insulin pens, syringes, pumps, and injectors market. Diabetes is a chronic condition where the body is unable to regulate blood sugar due to insufficient insulin production or ineffective use of insulin, leading to elevated blood sugar levels. The rise in diabetes cases is primarily attributed to increasingly sedentary lifestyles and the widespread consumption of high-calorie, unhealthy diets rich in sugars and fats, which contribute to obesity and insulin resistance. As more individuals are diagnosed with diabetes, the demand for insulin delivery devices-such as pens, syringes, pumps, and injectors-continues to grow, as these devices offer effective and convenient treatment. For example, in April 2025, the International Diabetes Federation, a Belgium-based organization representing over 240 national diabetes associations, reported that China had a total adult population of approximately 1.07 billion, with 11.9% of adults affected by diabetes. This equates to around 148 million cases of diabetes in adults. As such, the increase in diabetes prevalence globally is significantly driving the growth of the insulin delivery devices market.
Many companies operating in the insulin pens, syringes, pumps, and injectors market are focusing on technological advancements in insulin delivery systems to ensure effective and safe insulin administration. Insulin delivery systems are tools designed to provide insulin to diabetic patients, including devices such as pens, syringes, pumps, and injectors, ensuring precise and efficient blood sugar management. For instance, in June 2024, Insulet Corporation, a US-based medical equipment manufacturing company, launched the Omnipod 5, a tubeless automated insulin delivery system for individuals with type 1 diabetes aged two and older. It is the first system to integrate with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors, offering unique compatibility with these leading CGM brands for enhanced diabetes management.
In September 2023, Abbott Laboratories, a US-based medical device company, completed the acquisition of Bigfoot Biomedical Inc. for an undisclosed sum. This acquisition is part of Abbott's strategy to expand its presence in diabetes care and strengthen its portfolio of connected diabetes solutions. Bigfoot Biomedical Inc. is a US medical technology company specializing in the development and manufacturing of diabetes management systems, including insulin pens and syringes.
Major companies operating in the insulin pens, syringes, pumps and injectors market are Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Abbott Laboratories, Insulet Corporation, Sanofi Aventis, F. Hoffmann-La Roche Ltd, Becton Dickinson and Company, Animas Corporation, Ypsomed Holding AG, Dickinson and Company, Valeritas Inc., MannKind Corporation, Tandem Diabetes Care Inc., Biocon Ltd., B. Braun Melsungen AG, Terumo Corporation, Teleflex Incorporated, Nipro Corporation, Smiths Medical Inc., Owen Mumford, UltiMed Inc., Ypsomed Holding, Ascensia Diabetes Care, Trividia Health, ARKRAY Inc., AgaMatrix Inc., Medline Industries LP, Gerresheimer AG, West Pharmaceutical Services Inc., SHL Medical AG, Zhejiang POCTech Medical Co.Ltd., Jiangsu Wanhai Medical Instruments Co. Ltd.
North America was the largest region in the global insulin pens, syringes, pumps, and injectors devices and equipment market in 2025. Asia-Pacific was the second-largest region in insulin pens, syringes, pumps, and injectors devices and equipment market. The regions covered in the insulin pens, syringes, pumps and injectors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the insulin pens, syringes, pumps and injectors market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The insulin pens, syringes, pumps, and injectors market consist of sales of reusable pens, disposable pens, tubed pumps, and tubeless pumps that are used for injecting insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Insulin Pens, Syringes, Pumps And Injectors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses insulin pens, syringes, pumps and injectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for insulin pens, syringes, pumps and injectors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The insulin pens, syringes, pumps and injectors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.